IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Sunrest Lifescience IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in Ahmedabad and caters to Pharmaceutical sector. Mark Corporate Advisors Private is the merchant banker of Sunrest Lifescience IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 29th June 2023.
Sunrest Lifescience IPO posted revenues of Rs 22.56 crores and PAT of Rs 3.00 crores in FY24 on annualised basis.Financial results of Sunrest Lifescience IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Sunrest Lifescience IPO PAT Margin is 13.32%, ROCE (Return on Capital Employed) is [●]% as per latest financial. The below table shows Sunrest Lifescience IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Sunrest Lifescience IPO is Rs 36.05 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Sunrest Lifescience IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Sunrest Lifescience IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Sunrest Lifescience IPO is ₹36.05 Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Sunrest Lifescience IPO has a Price-to-Earnings (PE) ratio of 12.00 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Sunrest Lifescience IPO reported revenue of ₹22.56 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Sunrest Lifescience IPO provide insights into sales growth, market demand, and business scalability.
Sunrest Lifescience recorded an EBITDA of ₹ 4.00 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Sunrest Lifescience Profit After Tax (PAT) is ₹3.00 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 22.52 Cr.
EBITDA Margin:
17.76
%
Net Worth: ₹ 3.86 Cr.
Market Capitalisation:
₹ 36.05 Cr.
P/E:
12.00 times
P/BV: 2.45 times
EV/EBITDA: 9.73 times
Sunrest Lifescience operates in Pharmaceutical and Deal In Capsules, Tablets, Syrup, Ointment, Gel, Mouth Wash, Solution, Suspension, Dry Powders And Toothpaste.. The Issue is listed on NSE EMERGE in Nov, 2023. Sunrest Lifescience IPO size was 10.85 with Issue price of 84.00 .
Merchant Banker(s) of Sunrest Lifescience IPO: Mark Corporate Advisors Private Limited
Sunrest Lifescience IPO subscription was 48.54 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Sunrest Lifescience IPO listed at a listing price of 79.80 against the offer price of 84.00.
The current market price of Sunrest Lifescience is 51.90.
Why Us?
